MA53562A - Polythérapie destinée au traitement d'une maladie hépatique - Google Patents

Polythérapie destinée au traitement d'une maladie hépatique

Info

Publication number
MA53562A
MA53562A MA053562A MA53562A MA53562A MA 53562 A MA53562 A MA 53562A MA 053562 A MA053562 A MA 053562A MA 53562 A MA53562 A MA 53562A MA 53562 A MA53562 A MA 53562A
Authority
MA
Morocco
Prior art keywords
polytherapy
treatment
hepatic disease
hepatic
disease
Prior art date
Application number
MA053562A
Other languages
English (en)
Inventor
Allen Baharaff
Tali Gorfine
Liat Hayardeny-Nissimov
Original Assignee
Galmed Res And Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galmed Res And Development Ltd filed Critical Galmed Res And Development Ltd
Publication of MA53562A publication Critical patent/MA53562A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA053562A 2018-09-06 2019-09-03 Polythérapie destinée au traitement d'une maladie hépatique MA53562A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862727565P 2018-09-06 2018-09-06

Publications (1)

Publication Number Publication Date
MA53562A true MA53562A (fr) 2021-07-14

Family

ID=69722275

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053562A MA53562A (fr) 2018-09-06 2019-09-03 Polythérapie destinée au traitement d'une maladie hépatique

Country Status (12)

Country Link
US (1) US12239712B2 (fr)
EP (1) EP3846821B1 (fr)
JP (1) JP7900150B2 (fr)
KR (1) KR102876077B1 (fr)
CN (1) CN113164498A (fr)
AU (1) AU2019334939B2 (fr)
BR (1) BR112021004140A2 (fr)
CA (1) CA3111025C (fr)
IL (1) IL281244B2 (fr)
MA (1) MA53562A (fr)
MX (1) MX2021002655A (fr)
WO (1) WO2020049556A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020228577A1 (fr) * 2019-05-10 2020-11-19 深圳微芯生物科技股份有限公司 Dérivé de pyridazinone et son utilisation
WO2021204751A1 (fr) * 2020-04-06 2021-10-14 Poxel Combinaison pharmaceutique pour le traitement de maladies du foie
CN113698388B (zh) * 2020-05-20 2022-11-22 江苏恒瑞医药股份有限公司 6-氧代-1,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用
CN114437034A (zh) * 2020-11-06 2022-05-06 深圳微芯生物科技股份有限公司 一种酞嗪类化合物的可药用盐、晶型及其制备方法
CN114685450B (zh) * 2020-12-30 2026-06-16 昆药集团股份有限公司 2-吡啶酮类衍生物及其制备方法和在医药上的应用
TW202337470A (zh) * 2021-09-27 2023-10-01 美商瑪德瑞高製藥公司 用於縮減肝臟體積之瑞美替隆
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
WO2024251233A1 (fr) * 2023-06-08 2024-12-12 成都微芯药业有限公司 UTILISATION D'UN AGONISTE COMPLET DE PPAR EN COMBINAISON AVEC UN AGONISTE DE THR-β DANS LA RÉSISTANCE À DES MALADIES LIÉES AU MÉTABOLISME

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE480524T1 (de) * 2005-07-21 2010-09-15 Hoffmann La Roche Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten
MX2017008844A (es) * 2015-01-09 2018-03-14 Gilead Apollo Llc Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.
MX394463B (es) 2016-10-18 2025-03-19 Madrigal Pharmaceuticals Inc Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta.
US11197870B2 (en) * 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis

Also Published As

Publication number Publication date
CA3111025A1 (fr) 2020-03-12
MX2021002655A (es) 2021-05-27
IL281244B1 (en) 2025-01-01
IL281244A (en) 2021-04-29
CN113164498A (zh) 2021-07-23
IL281244B2 (en) 2025-05-01
BR112021004140A2 (pt) 2021-05-25
KR102876077B1 (ko) 2025-10-23
US20210338826A1 (en) 2021-11-04
EP3846821A1 (fr) 2021-07-14
CA3111025C (fr) 2023-10-31
EP3846821A4 (fr) 2022-05-25
JP7900150B2 (ja) 2026-08-04
WO2020049556A1 (fr) 2020-03-12
AU2019334939A1 (en) 2021-04-29
JP2022500366A (ja) 2022-01-04
US12239712B2 (en) 2025-03-04
AU2019334939B2 (en) 2025-03-27
EP3846821B1 (fr) 2023-10-04
KR20210057758A (ko) 2021-05-21

Similar Documents

Publication Publication Date Title
EP3846821A4 (fr) Polythérapie destinée au traitement d'une maladie hépatique
EP3880823A4 (fr) Virus adéno-associé thérapeutique pour le traitement de la maladie de pompe
MA54229A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
IL271046A (en) Compounds for treating huntington's disease
EP3790867A4 (fr) Inhibiteurs de kdm1a pour le traitement d'une maladie
MA55560A (fr) Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer
MA44864A (fr) Trithérapie pour le traitement d'une maladie intestinale inflammatoire
MA49906A (fr) Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie
EP3675859A4 (fr) Composés, compositions et méthodes pour le traitement d'une maladie
EP3558313A4 (fr) Substances pour le traitement d'affections liées à la stéatose hépatique
EP3405215A4 (fr) Méthodes destinées au traitement de la maladie de danon et d'autres troubles liés à l'autophagie
EP3718561A4 (fr) Agent thérapeutique pour une maladie inflammatoire de l'intestin
EP3737361A4 (fr) Inhibiteurs de la dihydrocéramide désaturase pour le traitement d'une maladie
EP3419622A4 (fr) Traitement d'une maladie neurodégénérative de l'oeil à l'aide de pridopidine
EP3432892A4 (fr) Antagonistes dérivés du mannose de fimh utiles pour le traitement d'une maladie
EP3630102A4 (fr) Formulations pour le traitement d'un trouble de stress post-traumatique
MA55199A (fr) Leucine, acétyl leucine et analogues apparentés pour le traitement d'une maladie
EP3405183A4 (fr) Dérivés d'adamatane pour le traitement d'une infection à filovirus
EP3504204A4 (fr) Indazolyl-l,2,4-thiadiazolamines et composés apparentés pour l'inhibition de protéine kinase associée à rho et le traitement de la maladie
MA54522A (fr) Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire
EP3773221A4 (fr) Traitement pour l'hydrocéphalie
EP3796980A4 (fr) Thérapie génique pour la maladie d'alzheimer
EP3648769A4 (fr) N-acyl amides dérivés du microbiote humain pour le traitement d'une maladie humaine
EP3781695A4 (fr) Importation d'arn mitochondrial pour le traitement d'une maladie mitochondriale
EP3638252A4 (fr) Activateurs dépendant de sting pour le traitement d'une maladie